Sustained effects of integrated COPD management on health status and exercise capacity in primary care patients by Kruis, Annemarije L et al.
© 2010 Kruis et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
International Journal of COPD 2010:5 407–413
International Journal of COPD Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
407
RevIew
open access to scientific and medical research
Open Access Full Text Article
DOI: 10.2147/COPD.S9654
Sustained effects of integrated COPD 
management on health status and exercise 
capacity in primary care patients
Annemarije L Kruis1
Joan van Adrichem2
Magda R erkelens2
Huub Scheepers3
Hans in ’t veen4
Jean wM Muris5
Niels H Chavannes1
1Department of Public Health and 
Primary Care, Leiden University 
Medical Center, Leiden, 2Physiotherapy 
Center De Beweging, Rotterdam, 
3well-being Medical Center, 
Bocholtz-Simpelveld, 4Department of 
Pulmonary Diseases, Sint Franciscus 
Gasthuis, Rotterdam, 5Department 
of General Practice, Maastricht 
University Medical Center,  
The Netherlands
Correspondence: Niels H Chavannes, 
MD PhD Associate Professor, 
Department of Public Health and Primary 
Care, Leiden University Medical Center, 
PO Box 9600, Zone v0-P, 2300 RC 
Leiden, The Netherlands
Tel +31 071 526 8444
Fax +31 071 526 8259
email n.h.chavannes@lumc.nl
Background: Chronic obstructive pulmonary disease (COPD) constitutes a growing health 
care problem worldwide. Integrated disease management (IDM) of mild to moderate COPD 
patients has been demonstrated to improve exercise capacity and health status after one year, 
but long-term results are currently lacking in primary care.
Methods: Long-term data from the Bocholtz study, a controlled clinical trial comparing the 
effects of IDM versus usual care on health status in 106 primary care COPD patients   during 
24 months of follow-up, were analyzed using the Clinical COPD Questionnaire (CCQ). 
In   addition, the Kroonluchter IDM implementation program has treated 216 primary care patients 
with mild to moderate COPD since 2006. Longitudinal six-minute walking distance (6MWD) 
results for patients reaching 24 months of follow-up were analyzed using paired-sample t-tests. 
In prespecified subgroup analyses, the differential effects of baseline CCQ score, Medical 
Research Council (MRC) dyspnea score, and 6MWD were investigated.
Results: In the Bocholtz study, subjects were of mean age 64 years, with an average 
  postbronchodilator forced expiratory volume in one second (FEV1) of 63% predicted and an 
FEV1/forced vital capacity (FVC) ratio of 0.56. No significant differences existed between groups 
at baseline. CCQ improved significantly and in a clinically relevant manner by 0.4 points over 
24 months; effect sizes were doubled in patients with CCQ . 1 at baseline and tripled in patients 
with MRC dyspnea score .2. In the Kroonluchter cohort, 56 subjects completed follow-up, were 
of mean age 69 years, with an FEV1/FVC ratio of 0.59, while their postbronchodilator FEV1 
of 65% predicted was somewhat lower than in the total group. 6MWD improved significantly 
and in a clinically relevant manner up to 93 m at 12 months and was sustained at 83 m over 
24 months; this effect occurred faster in patients with MRC dyspnea score .2. In patients with 
baseline 6MWD , 400 m the improvement remained .100 m at 24 months.
Conclusion: In this study, IDM improved and sustained health status and exercise capacity in 
primary care COPD patients during two years of follow-up. Improvements in health status are 
consistently higher in patients with CCQ . 1 at baseline, being strongest in patients with base-
line MRC dyspnea score .2. Improvements in exercise capacity remain highest in patients with 
6MWD , 400 m at baseline and seem to occur earlier in patients with MRC dyspnea score .2.
Keywords: chronic obstructive pulmonary disease, disease management, integrated care, 
pulmonary rehabilitation, primary care
Background
Chronic obstructive pulmonary disease (COPD) constitutes a major and progressive 
health care problem worldwide and is expected to be the third cause of death glob-
ally over the next 20 years.1 Besides smoking cessation, pulmonary rehabilitation is 
the recommended treatment and has been proven to be effective across the whole International Journal of COPD 2010:5 submit your manuscript | www.dovepress.com
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spectrum of COPD patients.2–5 A recent meta-analysis shows 
that pulmonary rehabilitation relieves dyspnea and fatigue, 
improves mental status, and enhances patients’ control over 
their disease.6 However, despite proven efficacy, pulmonary 
rehabilitation is still only available for a small proportion 
of the worst patients, due to   capacity   problems and high 
costs.7 It is expected that the rise in prevalence of COPD will 
progressively cause an even higher burden on rehabilitation 
programmers in the future.
At present, the majority of COPD patients are treated in 
primary care, and approximately 80% suffer from mild to 
  moderate disease.8 As a result, general practitioners often find 
themselves at a crossroads in the organization of care for COPD 
patients. Nevertheless, interdisciplinary cooperation between 
primary health care providers, as well as primary and second-
ary care, is often needed. In earlier reports9,10 we hypothesized 
that if components of pulmonary rehabilitation were tailored 
into an integrated disease management (IDM) program avail-
able for primary care and carried out by a multidisciplinary, 
integrated care team, the benefits of pulmonary rehabilitation 
could be extended to a larger population of COPD patients in 
need. This would explicitly include those with milder stages 
of disease, given that they have   sufficient symptom burden to 
justify an integrated   intervention. Elements that can often be 
integrated include smoking cessation, exacerbation manage-
ment, optimal medication, self-management, patient education, 
dietary intervention, and an exercise program.
In an earlier paper, we demonstrated that our IDM program 
in primary care improved health status in a clinically relevant 
way in patients with mild to moderate COPD at 12 months’ 
follow-up. The greatest room for improvement was shown 
in COPD patients with a   Medical Research   Council (MRC) 
dyspnea score .2.9 After we had   demonstrated 12 months’ 
efficacy of the IDM program in a controlled setting, a real-life 
implementation cohort was set up in the city of Rotterdam. 
In this pragmatic IDM   program, we focused on improving 
  exercise capacity because we believed this would be an impor-
tant driver to sustain   effectiveness. Currently,   long-term results 
of pulmonary rehabilitation programs are mixed, and some 
authors report that most benefits of   pulmonary rehabilitation 
dissipate over time.11–13 Similarly, the   longer-term effect of 
IDM in primary care is still unclear. The aim of the present 
study was to determine the long-term effects of IDM on health 
status and exercise capacity in primary care COPD patients.
Methods
We analyzed 24 months of follow-up data for primary care 
IDM programs in the Bocholtz controlled clinical trial and the 
Kroonluchter implementation cohort. Both study populations 
consisted of primary care patients with chronic respiratory 
symptoms and a postbronchodilator forced expiratory volume 
in one second/forced vital capacity (FEV1/FVC) , 0.7, in 
accordance with national and international guidelines.3,8 
Exclusion criteria were terminal illness, immobility, sub-
stance abuse, and inability to fill in questionnaires. In the 
Bocholtz clinical trial, the regional Medical Ethics Com-
mittee of the Atrium Medical Centre, Heerlen, approved the 
study protocol. All participating patients gave their written 
informed consent. In the Kroonluchter cohort, all patients 
gave their written informed consent for participation in the 
implementation program.
In the following section we provide a brief description of 
both study settings and designs. We refer to our   previous pub-
lications for an extensive description of the clinical   one-year 
results and methods for the Bocholtz study,9 as well as the 
background and design of the Kroonluchter IDM program.10
Picasso Bocholtz study
The Picasso Bocholtz study was a controlled clinical trial 
assessing the effects of IDM on health status in COPD 
patients from two comparable primary health care centers in 
the south of The Netherlands. Patients were followed up for 
two years, during which time the intervention group received 
an IDM program and the control group received usual 
care. Patients were included based on chronic respiratory 
complaints, postbronchodilator lung function testing, and 
adequate workup in case of more complex disease by a local 
pulmonologist, on indication by the patients’ primary care 
physician. In the intervention setting, an integrated COPD 
management team was formed, including two physiothera-
pists, a respiratory nurse, a physician assistant, a dietician, 
a pharmacist, a supervising primary care physician, and a 
logistics manager. All team members contributed in their 
area of expertise to a standardized written treatment protocol, 
which included different elements of IDM, based on the joint 
American Thoracic Society/European Respiratory Society 
COPD standards.14 Examples included personalized physical 
activity training programmers, optimal medication prescrib-
ing and adherence monitoring, rapid action plans for exacer-
bations, and continuous self-management education.9
Kroonluchter cohort
Based on the encouraging results of the Bocholtz study, 
the Kroonluchter integrated disease management program 
was implemented in a low socioeconomic status borough in 
  Rotterdam. Since 2006, a total of 216 primary care patients International Journal of COPD 2010:5 submit your manuscript | www.dovepress.com
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with chronic respiratory complaints have been included 
after clinical assessment, including postbronchodilator lung 
  function testing, confirmed eligibility according to GOLD 
(Global Initiative for Chronic Obstructive Lung Disease) 
criteria. A multidisciplinary dedicated team of primary care 
physicians, nurse specialists, and physiotherapists was formed 
and trained to establish a locally agreed collaborative protocol. 
Diagnostic workup in case of complex disease was provided 
by collaborating pulmonologists, after referral by the primary 
care physician. In cooperation with the patient, an individu-
alized plan of action was designed, based on an explicitly 
formulated personal target, varying from “quitting smoking 
with guidance within six months” to “climbing a short flight 
of stairs without hindrance by feelings of dyspnea within 
six months”. Based on disease burden and patient needs, 
an individual program was assembled, which could include 
self-management training and exacerbation management, an 
exercise training program, smoking cessation strategies, better 
medication use, and personalized disease education.
In case of obesity or muscular depletion, referral to a dieti-
cian for dietary intervention was possible. Because of good 
local collaboration and arrangements for additional workup, 
patients could be referred to pulmonary physicians at short 
notice. In addition, extra attention was given to follow-up of 
patients after an exacerbation. Patients with an MRC dyspnea 
score .2 or patients known by their primary care physician 
to be inactive were assigned to a six-month COPD-specific 
training program run by specialized physiotherapists. Physi-
cal exercise training consisted of one month of individual 
training, followed by five months of group training. Training 
was focused on strength as well as endurance exercises, and 
was tailored to the individual abilities and limitations of the 
patient. Patients trained for one hour twice per week under 
supervision and were instructed to train one hour per week 
at home. After six months, there was a follow-up of one hour 
per week in order to sustain any effects over time.10
Outcomes and measurements
Baseline measurements in both studies included age, gender, 
smoking habits, body mass index, lung function, and score 
on the MRC dyspnea scale (a short and valid questionnaire 
to quantify dyspnea).15
In the Bocholtz study, the Clinical COPD Question-
naire (CCQ) was used to assess health status, because it 
is well validated and easy to administer in primary care.15 
Primary outcome at 24 months in the Bocholtz study was 
the   difference in CCQ at 24 months compared with baseline 
CCQ score in both the intervention and control groups.
In the Kroonluchter cohort, the six-minute walking 
distance (6MWD), a measure of functional capacity, was 
conducted according to international recommendations.16 
The 6MWD is a practical, self-paced test, measuring the 
  maximum distance subjects can walk in six minutes. The 
  primary outcome of this program was the difference in 6MWD 
at 24 months compared with baseline 6MWD score.
Power calculations
In the Bocholtz study, we calculated that a sample size 
of 2 × 45 patients was needed (with a power of 80% and 
α = 0.05) to detect a minimum clinically important difference 
of -0.4 unit change in quality of life on the CCQ.15
Because the Kroonluchter project was designed as an 
ongoing implementation program, no formal group com-
parison or power calculation was conducted. On the basis of 
earlier studies and a minimum clinically important difference 
of 54 m, which represents the threshold value for a clinically 
significant change on the 6MWD,16 a minimum group size 
of 50 patients was deemed necessary to analyze 24-month 
results. In this study, the first batch of consecutive COPD 
patients completing 6MWD measurements at baseline and 
months 3, 6, 12, and 24 were analyzed.
Statistical analysis
Data were analyzed using SPSS version 13, using indepen-
dent t-tests and Chi-square tests for comparison of baseline 
characteristics. Baseline and annual differences in CCQ 
(Bocholtz) and 6MWD (Kroonluchter) were compared using 
paired-sample t-tests. In prespecified subgroup analyses, the 
differential effects of baseline CCQ score, MRC score, and 
6MWD were investigated.
Results
Patients
In the Bocholtz study, 106 COPD patients diagnosed accord-
ing to GOLD classification were analyzed for baseline 
measurements, comprising 59 patients in the intervention 
group and 47 patients in the control group. This initial COPD 
population is described in Table 1. Subjects were of mean age 
64 years, with an average postbronchodilator FEV1 of 63% 
predicted (standard deviation 19) and an FEV1/FVC ratio of 
0.56. There were no significant differences in demographic 
variables, smoking habits, or lung function between the 
intervention and control groups at baseline. Of the initial 
population of 106 patients, 86 patients (81%) completed a 
follow-up of two years (44 in the intervention group and 42 in 
the control group) and could be further analyzed.International Journal of COPD 2010:5 submit your manuscript | www.dovepress.com
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Of the original group of 216 patients in the Kroonluchter 
cohort, 39 (18%) dropped out due to relocation, severe comor-
bidity, or unwillingness to fill out repeated questionnaires. Of 
the initial 216 patients, 104 (48%) were referred to a physio-
therapy training program, based on MRC dyspnea score .2 
or inactivity that necessitated an integrated approach. So far, 
56 patients (54%) have completed the 24-month 6MWD test, 
and their data could be used for analysis. Table 2 shows the 
baseline characteristics of the initial cohort and the group 
that finished 24 months of follow-up. The mean age of the 
latter group was 69 years, with an FEV1/FVC ratio of 0.59, 
while their postbronchodilator FEV1 of 65% was somewhat 
lower than in the total group (71%).
Primary outcome in Bocholtz study
Table 3 shows the long-term changes in CCQ scores in 
COPD patients in the intervention and control groups of 
the Bocholtz study. Compared with baseline, a statistically 
significant change of -0.4 is sustained in the intervention 
group during 24 months, while the control group shows 
nonsignificant changes during 24 months. The prespecified 
subgroup analysis of patients with baseline CCQ . 1 shows 
a   statistically significant and clinically relevant   difference 
of -0.9, while the control group shows no significant 
improvement. In patients with MRC scores .2, the effect 
on CCQ score is tripled and shows a statistically significant 
and clinically relevant difference of -1.2, compared with a 
nonsignificant change of -0.02 in the control group.
Primary outcome in Kroonluchter cohort
Table 4 shows the long-term changes in 6MWD in the 
Kroonluchter cohort at months 3, 6, 12, and 24. The 6MWD 
improves significantly and in a clinically relevant manner up 
to 93 m at 12 months, and remains at 83 m over 24 months. In 
patients with MRC scores .2, 6MWD differences are com-
parable in significance and clinical relevance, but seem to 
occur somewhat earlier, ie, at three months. In patients with 
baseline 6MWD , 400 m, the 6MWD   difference is 112 m at 
12 months and remains statistically significant and clinically 
relevant at 24 months, with effect sizes over 100 m.
Discussion
Our studies demonstrate that IDM programs can be suc-
cessfully implemented in real-life primary care   populations. 
Even after two years, considerable proportions of the 
patients involved in the programs still show significant and 
  clinically relevant improvements in health status and exercise 
  tolerance. In patients with a baseline CCQ . 1 and in those 
with MRC dyspnea score .2, the long-term effect on CCQ 
score seems to be doubled and even tripled, respectively. 
In patients with baseline 6MWD , 400 m, the 6MWD 
difference remains substantially large over two years, with 
effect sizes exceeding 100 m.
A typical structured program of pulmonary rehabilitation 
in the secondary and tertiary care setting is usually of rela-
tively short duration, ranging from 6 to 12 weeks.17 Positive 
results up to three months have been widely published,6,17–19 
but several clinical trials have reported that initial benefits 
of the intervention tend to recede over time, and that effects 
above clinical relevance thresholds are lost again at six to 
18 months’ follow-up.11–13,20,21
As a result, recommendations regarding prolonged 
duration of pulmonary rehabilitation have been issued, and 
several studies have evaluated longer-term programs in more 
severe patients, with inconclusive results. Guell randomized 
Table 1 Baseline characteristics of intervention versus control 
group in primary care COPD patients of the Bocholtz study*
Intervention 
(n = 59)
Control 
(n = 47)
P value#
Age (years) 64.7 (10) 62.3 (9) 0.99
Gender (% male) 66.4 64.3 0.12
Current smoking (%) 33.9 46.8 0.08
Body mass index 25.8 (5) 26.0 (5) 0.75
Fev1 post-BD (%) 63.9 (21) 61.7 (17) 0.06
Fev1/FvC post-BD 0.55 (.10) 0.57 (.10) 0.72
MRC . 2 (%) 38.6 33.3 0.32
CCQ 1.4 (1) 1.6 (1) 0.75
Notes: *All values are means (SD) except when stated otherwise; #no significant 
difference between groups at baseline. 
Abbreviations: MRC, Medical Research Council dyspnea score; CCQ, Clinical 
COPD Questionnaire; SD, standard deviation; Fev1, forced expiratory volume in 
one second; FvC, forced vital capacity; BD, bronchodilator.
Table 2 Baseline characteristics of total versus 6MwD group in 
primary care COPD patients of the Kroonluchter cohort*
Total (n = 216) 6MWD (n = 56) P value
Age (years) 67.1 (14) 69.2 (10) 0.11
Gender (% male) 42.1 37.3 0.38
Current smoking (%) 41.2 33.3 0.78
Body mass index 27.3 (6) 27.8 (5) 0.45
Fev1 post-BD (%) 70.5 (18) 64.5 (17) 0.002#
Fev1/FvC post-BD 0.61 (.12) 0.59 (.14) 0.098
MRC . 2 (%) 45.8 51.9 0.24
6MwD (m) 364.0 (128) 354.6 (126) 0.44
Notes:  *All  values  are  means  (SD)  except  when  stated  otherwise;  #significant 
difference between groups at baseline. 
Abbreviations:  COPD,  chronic  obstructive  pulmonary  disease;  MRC,  Medical 
Research Council dyspnea score; 6MwD, six-minute walking distance; SD, standard 
deviation; Fev1, forced expiratory volume in one second; FvC, forced vital capacity; 
BD, bronchodilator.International Journal of COPD 2010:5 submit your manuscript | www.dovepress.com
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60 GOLD Stage III COPD patients to 12 months of interven-
tion or standard care and followed them up for two years. 
Benefits on exercise tolerance, dyspnea, and quality of life 
were accrued, but diminished in the second year of follow-up.22 
In a randomized controlled study in moderate to very severe 
COPD patients, Berry et al concluded that an 18-month 
exercise program resulted in greater improvements in self-
reported disability and physical functioning when compared 
with a three-month exercise program.4 Wijkstra et al reported 
improvements in quality of life over 18 months in GOLD 
Stage III patients following rehabilitation at home for three 
months, followed by physiotherapy sessions once a month. 
However, the authors concluded that change in quality of 
life was not associated with a change in exercise tolerance.23 
Positive findings in selected patient groups in secondary and 
tertiary care, following a prolonged pulmonary rehabilitation 
program, were further confirmed by Troosters et al, Engstrom 
et al, and Bendstrup et al, suggesting that structured, supervised 
exercise participation should be continued for extended periods 
in patients undergoing pulmonary rehabilitation.24–26
To the best of our knowledge, this is the first study 
describing long-term follow-up results of IDM in primary 
care. Our positive results can be explained by two important 
differences, as compared with the mixed results summa-
rized earlier. First, we studied the effect of IDM programs 
developed especially for primary care, which consist of an 
interdisciplinary approach involving different primary health 
care team members, aided by secondary care where needed. 
Furthermore, other pulmonary rehabilitation studies usually 
included more severe COPD patients, while our programs 
were directed at the whole range of COPD patients, includ-
ing those with milder stages of disease, but with sufficient 
symptom burden to justify intervention.
Our results are probably more in line with the recent 
INTERCOM (Interdisciplinary Community-Based COPD 
Management Program) study that included secondary care 
COPD patients with less advanced airflow obstruction, but 
impaired exercise capacity. In this randomized controlled 
trial, the intervention group received exercise training, educa-
tion, nutritional therapy, and smoking cessation counseling in 
a community-based, multidisciplinary setting. Quality of life, 
functional exercise capacity, and breathlessness remained 
significantly favorable in the intervention group versus usual 
care over the entire two-year intervention.27
Table 3 Long-term effects of integrated disease management on health status in primary care COPD patients of the Bocholtz study*
Intervention group  P value Control group  P value
CCQ difference*/95% CI CCQ difference**/95% CI
All patients
12 mo -0.4 (-0.6, -0.2) 0.001 +0.01 (-0.2, 0.2)  0.9
24 mo -0.4 (-0.7, -0.1) 0.004 +0.02 (-0.4, 0.5)  0.9
Subgroup baseline CCQ . 1
12 mo -0.8 (-1.1, -0.4)  0.001 -0.1 (-0.3, 0.08)  0.2
24 mo -0.9 (-1.2, -0.5)  0.001 -0.03 (-0.5, 0.5)  0.9
Subgroup baseline MRC . 2
12 mo -0.9 (-1.4, -0.4)  0.002 +0.01 (-0.3, 0.3)  1.0
24 mo -1.2 (-1.8, -0.5)  0.004 -0.02 (-0.8, 0.8)  1.0
Notes: *Paired samples t-test; P is considered significant at values , 0.05; **minimum clinically important difference CCQ = -0.4.15 
Abbreviations: CCQ, Clinical COPD Questionnaire; CI, confidence interval; MRC, Medical Research Council dyspnea score.
Table 4 Long-term effects of integrated disease management on 
exercise tolerance in primary care chronic obstructive pulmonary 
disease patients of the Kroonluchter cohort*
6MWD difference** 
compared with baseline 
(95% CI)
P value
All patients
3 mo 38.3 (27.2, 49.4) ,0.0001
6 mo 62.5 (47.4, 77.7) ,0.0001
12 mo 93.5 (71.4, 115.6) ,0.0001
24 mo 83.3 (60.0, 106.6) ,0.0001
Subgroup baseline  
MRC . 2
3 mo 52.1 (37.1, 67.2) ,0.0001
6 mo 59.2 (40.8, 77.7) ,0.0001
9 mo 93.0 (62.9, 123.1) ,0.0001
12 mo 80.0 (44.7, 115.3) ,0.0001
Subgroup baseline  
6MwD , 400 m
3 mo 52.7 (38.9, 66.5) ,0.0001
6 mo 78.2 (52.5, 103.9) ,0.0001
9 mo 112.3 (77.9, 146.7) ,0.0001
12 mo 101.4 (64.3, 138.6) ,0.0001
Notes:  *Paired-samples  t-test;  P  is  considered  significant  at  values  ,0.05; 
**6MwD = 54 m.17 
Abbreviations:  6MWD,  six-minute  walking  distance;  CI,  confidence  interval; 
MRC, Medical Research Council dyspnea score.International Journal of COPD 2010:5 submit your manuscript | www.dovepress.com
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It is well known that COPD patients have a less active 
lifestyle compared with healthy elderly persons.28 One study 
by Pitta et al showed that significant improvements in time 
spent walking in daily life were only obtained after six months 
of rehabilitation, but were not present at three months.29 These 
findings are mirrored in our Kroonluchter cohort results for 
the 6MWD, stressing the importance of implementing pro-
grams for at least six months to optimize the potential for 
improvement. It is likely that benefits achieved after following 
an exercise program tend to dissipate after the initial inter-
vention and when the accompanying supervision terminates. 
Therefore, we successfully developed a training program 
which included extra follow-up training of one hour per week 
after the initial six months, intended to enhance social support 
in the training groups and sustain results in the long term. It 
is likely that our clinically relevant and statistically significant 
results on the 6MWD at 24 months of follow-up are the result 
of more prolonged supervision by physiotherapists and the 
peer support offered in the training groups.
Our studies had several methodologic limitations. The 
Bocholtz program was designed as a clinical controlled trial, 
but was not randomized, because it was primarily developed 
to measure a maximally achievable effect of an IDM program 
at a primary care practice level. Indeed, the study setting was 
chosen to include demographically comparable villages but 
with limited interaction in daily life, resulting in near absence 
of contamination between groups.12 The Kroonluchter cohort 
was based on lessons learned from the Bocholtz study, and 
was primarily developed as an implementation program in a 
real-life setting. As a result, a power calculation was not done 
beforehand. Nevertheless, our significant 6MWD results at 
24 months reached far beyond the minimum clinically impor-
tant difference of 54 m, demonstrating an adequate sample 
size. The first adequate batch of consecutive COPD patients 
completing 6MWD measurements at 24 months analyzed 
in this study may represent selection of more motivated 
patients, although their baseline characteristics differed little 
from the total group (see Table 2). Indeed, we have observed 
that higher levels of intrinsic motivation usually come with a 
higher burden of symptoms at baseline. This may be part of 
the reason that indicators of disease burden (CCQ . 1, MRC 
dyspnea score .2, 6MWD , 400 m) do seem to increase 
the chances of achieving clinically relevant effects on health 
status in patients with mild to moderate COPD. These results 
suggest a potential usefulness of phenotypic profiling in a 
primary care COPD population, which we intend to study 
further, and we recommend that other research groups do 
so as well.
Regaining control over one’s own disease state is prob-
ably a crucial factor in the success of both of our programs. 
During the IDM program, improved feelings of self-efficacy 
and independence became notable in participating patients. 
Overall, the greatest improvements were found in patients 
with a baseline MRC dyspnea score .2, and to a lesser 
extent in patients with CCQ . 1. At this stage, lung function 
is still relatively well maintained and thus patients perceive 
a tangible change in symptom burden. When asked, they 
felt more capable of actually breaking through the vicious 
circle of inactivity, anxiety, and increasing dyspnea. This was 
prominently reflected in the patient group with a baseline 
6MWD below 400 m, who have achieved the most dramatic 
improvements in exercise capacity. This cutoff was in fact 
more sensitive than the 350 m cutoff point used in the BODE 
(body mass index, obstruction, dyspnea, exercise) index, 
probably reflecting more room for improvement in primary 
care COPD patients.30
When COPD patients are treated with IDM at an earlier 
stage, it is likely that costs per patient will be lower, and that 
larger groups of eligible patients can benefit. Further disease 
progression in terms of health status and exercise capacity 
will be positively influenced and, if sustained, even long-term 
deterioration of lung function may be reduced. We have dem-
onstrated that teams of general practitioners, physiotherapists, 
and nurse practitioners, supported by pulmonary physicians, 
can provide adequate IDM designed for primary care, because 
patients’ health status and   exercise capacity improved sub-
stantially, even after two years of follow-up. In the future, we 
therefore recommend pragmatic randomized   controlled trials 
addressing the costs and long-term effectiveness of large-scale 
IDM programs in primary care.
Conclusion
In this study, IDM improved and sustained health status 
and exercise capacity in primary care COPD patients 
during two years of follow-up. Improvements in health 
status were consistently higher in patients with CCQ . 1 
at baseline, being strongest in patients with MRC dyspnea 
score .2. Improvements in exercise capacity remain 
highest in patients with 6MWD , 400 m at baseline 
and seem to occur earlier in patients with MRC dyspnea 
score .2.
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